Mesoblast (MSB)

Download button icon Download

Mesoblast (MSB): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Mesoblast (MSB.AX)


Indicator:

VOLUME RATE OF CHANGE


Last Signal:

BULLISH


Trading: HOLD @ $1.31
Signal Strength: MEDIUM
Recommendation:

Mesoblast (ASX:MSB) currently has positive volume of change of 51%. This means the current volume is greater than the price 14 days ago and therefore gaining momentum.

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement


Volume Rate of Change Volume (VROC) is an oscillator applied to volume rather than price and is calculated in the same manner as the Rate of Change (Price) indicator. VROC highlights increases in volume which normally occur at most significant market tops bottoms and breakouts.

Calculation: Volume Rate of Change (VROC):
1) ( Volume [today] - Volume [n days ago] ) / Volume [n days ago];


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Volume Rate of Change

Download button icon Download
Company Close Change (%) Volume Value Signal
PME Pro Medicus 9.56 4.3 157,145 35 BULLISH CROSSOVER
AKP Audio Pixels Holdings 18 4 4,620 157 BULLISH CROSSOVER
OSP Osprey Medical 0.15 3.6 43,001 24,883 BULLISH CROSSOVER
ERA Energy Resources Of Australia 0.32 3.2 247,616 230 BULLISH CROSSOVER
GAP Gale Pacific 0.38 2.7 49,402 358 BULLISH CROSSOVER
RCT Reef Casino 3.3 2.5 9,698 4,073 BULLISH CROSSOVER
QVE QV Equities 1.08 2.4 160,691 110 BULLISH CROSSOVER
MAH Macmahon 0.26 2 1,152,052 94 BULLISH CROSSOVER
BDR Beadell Resources 0.05 2 1,226,594 274 BULLISH CROSSOVER
SPK Spark New Zealand 3.92 1.6 904,798 61 BULLISH CROSSOVER
back to top